Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.00 (-0.74%)
Close on Nov 17, 2026Market cap $53.58MP/E –Yield –
Heron Therapeutics cash
Cash and short-term investments held at the end of each period.
Heron Therapeutics's cash was $42.70M at Jun 30, 2026. For fiscal 2025 it was $46.60M, down 21.4% from the year before. Over ten years it grew -9.8% a year on average. The highest annual figure on record is $391.00M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.60M | -21.4% |
| FY2024 | Dec 31, 2024 | $59.30M | -26.2% |
| FY2023 | Dec 31, 2023 | $80.40M | -5.3% |
| FY2022 | Dec 31, 2022 | $84.90M | -46.1% |
| FY2021 | Dec 31, 2021 | $157.60M | -24.4% |
| FY2020 | Dec 31, 2020 | $208.50M | -46.7% |
| FY2019 | Dec 31, 2019 | $391.00M | +17.6% |
| FY2018 | Dec 31, 2018 | $332.40M | +92.8% |
| FY2017 | Dec 31, 2017 | $172.40M | +237.4% |
| FY2016 | Dec 31, 2016 | $51.10M | -61.1% |
| FY2015 | Dec 31, 2015 | $131.20M | +80.5% |
| FY2014 | Dec 31, 2014 | $72.68M | +0.5% |
| FY2013 | Dec 31, 2013 | $72.29M | +35.1% |
| FY2012 | Dec 31, 2012 | $53.51M | +197.7% |
| FY2011 | Dec 31, 2011 | $17.97M | +752.3% |
| FY2010 | Dec 31, 2010 | $2.11M | -72.2% |
| FY2009 | Dec 31, 2009 | $7.59M | -23.8% |
| FY2008 | Dec 31, 2008 | $9.97M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $42.70M | +5.2% |
| Q1 FY2026 | Mar 31, 2026 | $44.80M | -11.6% |
| Q4 FY2025 | Dec 31, 2025 | $46.60M | -21.4% |
| Q3 FY2025 | Sep 30, 2025 | $55.50M | -21.7% |
| Q2 FY2025 | Jun 30, 2025 | $40.60M | -39.7% |
| Q1 FY2025 | Mar 31, 2025 | $50.70M | -29.1% |
| Q4 FY2024 | Dec 31, 2024 | $59.30M | -26.2% |
| Q3 FY2024 | Sep 30, 2024 | $70.90M | -8.4% |
| Q2 FY2024 | Jun 30, 2024 | $67.30M | +102.7% |
| Q1 FY2024 | Mar 31, 2024 | $71.50M | +19.2% |
| Q4 FY2023 | Dec 31, 2023 | $80.40M | -5.3% |
| Q3 FY2023 | Sep 30, 2023 | $77.40M | -36.4% |
| Q2 FY2023 | Jun 30, 2023 | $33.20M | -60.2% |
| Q1 FY2023 | Mar 31, 2023 | $60.00M | -46.4% |
| Q4 FY2022 | Dec 31, 2022 | $84.90M | -46.1% |
| Q3 FY2022 | Sep 30, 2022 | $121.70M | -40.0% |
| Q2 FY2022 | Jun 30, 2022 | $83.50M | -67.6% |
| Q1 FY2022 | Mar 31, 2022 | $111.90M | -32.8% |
| Q4 FY2021 | Dec 31, 2021 | $157.60M | -24.4% |
| Q3 FY2021 | Sep 30, 2021 | $202.80M | -21.4% |
| Q2 FY2021 | Jun 30, 2021 | $257.70M | -14.3% |
| Q1 FY2021 | Mar 31, 2021 | $166.50M | -53.3% |
| Q4 FY2020 | Dec 31, 2020 | $208.50M | -46.7% |
| Q3 FY2020 | Sep 30, 2020 | $258.10M | +0.7% |
| Q2 FY2020 | Jun 30, 2020 | $300.80M | +9.0% |
| Q1 FY2020 | Mar 31, 2020 | $356.30M | +23.2% |
| Q4 FY2019 | Dec 31, 2019 | $391.00M | +17.6% |
| Q3 FY2019 | Sep 30, 2019 | $256.30M | -29.7% |
| Q2 FY2019 | Jun 30, 2019 | $276.00M | -34.8% |
| Q1 FY2019 | Mar 31, 2019 | $289.20M | +153.9% |
| Q4 FY2018 | Dec 31, 2018 | $332.40M | +92.8% |
| Q3 FY2018 | Sep 30, 2018 | $364.80M | +393.0% |
| Q2 FY2018 | Jun 30, 2018 | $423.00M | +287.0% |
| Q1 FY2018 | Mar 31, 2018 | $113.90M | -31.1% |
| Q4 FY2017 | Dec 31, 2017 | $172.40M | +237.4% |
| Q3 FY2017 | Sep 30, 2017 | $74.00M | -16.8% |
| Q2 FY2017 | Jun 30, 2017 | $109.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $165.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $51.10M | – |
| Q3 FY2016 | Sep 30, 2016 | $88.90M | – |
See a number that looks wrong?